Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amarin needs a pricing strategy or an authorized generic V to regain US market share. how long can they keep building inventory which they must be doing to maintain minimum purchase per agreement with falling sales to boot? This is the sorriest management I could ever have imagined. Such a wasted opportunity.
ffs, what will it take for AMRN to break its downtrend and start a prolonged rally?
marjac, when is the filing deadline for our writ?
It sounds so reasonable when you explain it, why is it so hard for the courts to understand it?
Sorry, dumb question I know, but I'm just numb from this stocks price action and the lack of management concern or initiative.
on a new subject, I will not be surprised when 1st quarter 13g is filed that Denner has abandoned ship. hard to create a $15 BO of a $3 company run by a bunch of clowns. The COB should be sued. hard to believe he is still chairman of either Amarin or Sofinova.
Is Vascepa approved for stroke/risk?
Show me the chart.
Is Vascepa good for a broken heart?
very good, sorry, great! I hope you are being compensated.
Will someone please explain:
1) Why no one has done a comparative composition study of gv versus V?
2) why Amarin has not created an authorized Vascepa generic?
MMS, where the hell is the authorized generic?
The first 2 blood tests would seem to be mandatory:
https://articles.mercola.com/sites/articles/archive/2022/03/12/overlooked-lab-tests.aspx?ui=ff340c8dbd45cc819d4a24e4c8404772abc3ca8f52ef1a47742a0bc8bfe56f7a&sd=20150731&cid_source=dnl&cid_medium=email&cid_content=art3ReadMore&cid=20220312&mid=DM1132090&rid=1431540980
Do we have the results of ENHANCE-IT? If not when will they be released as the trial completion date passed and it was a very small trial.
Is MITIGATE not a worthy catalyst?.
Raf, Capt, thank you both for the script numbers and graphs. It sure is discouraging that we have less than 45% of the Omega-3 market and even less of the trig market if we include fibrates and niacin.
LB, Has this link been put on stock twits or Twitter?.
when should we anticipate the NICE decision? any day now or some pre-specified day?
72666
certiiorari fund now 25%. we can do better than this.
study, thank you very much, very enlightening.
How can an investor in this stock be thousands below cost and not want to wager a $100 on the writ of certiorari effort in hopes of gaining a large portion of those losses back?
GoFundMe
https://gofund.me/7fbd75d3
What time is NICE meeting? Should we anticipate Nissen being there to sabotage us?
What I don't comprehend are Amarin shareholders that are thousands of dollars underwater that are hesitant to risk $100 in the final (?) effort to find justice through the writ of certiorari. Admittedly it is a long shot, but it's worth the price of a lottery ticket. the gofundme page is below.
https://www.gofundme.com/f/epadi-ii-certiorari-us-supreme-court?member=17851399&utm_campaign=p_cp+share-sheet&utm_medium=copy_link_all&utm_source=customer
Kiwi, if Kaiser is not prescribing gl for high trigs, what are they prescribing, fenofibtates? I’m just trying to get a feel as to what their incremental uptake of V might be if MITIGATE is successful. If they are prescribing a lot of V already, they would not have to run MITIGATE, just mine their data. No?
Pdude , what are your expectations for MITIGATE results when reported April 2?
a major holding, or an afterthought?
It would be nice if Dr. Bhatt was one of the presenters, but highly unlikely. I'm filled with trepidation that our august management will blow this. I can only pray that I'm wrong.
OT given your insight into Kaiser:
I assume Kaiser has Lovaza on their formulary and that they have all sorts of data on patients and prescriptions, etc.
would it be conceivable if MITIGATE results were to be very good, that they would/could instruct doctors in the system to stop prescribing Lovaza and switch patients to Vascepa?
Just an uneducated query.
Thanks. I was hoping to see a slight upward bend in V’s curve, but no such luck. I can’t believe the gl trend. Will doctors never learn?
Capt. can you/ do you show a chart just showing NRx for these three groups of scripts? such a chart would focus on Amarin's new/current marketing thrust. TIA.
Good insight, thank-you
Does Vascepa act as a GSK-3 inhibitor? There are so many biochem abbreviations that I get lost as to which are which. Thanx.
The only way to get a "fair price" in the low $20s would be for MITIGATE to have a strong showing and Dr. Mason shows that gv is in no way a bioequivalent, that gets us to high single-digit or low double-digit. Europe will be slow growth given the geopolitical environment, and Eddingham will also likely not be able to finance in the near term, so China's delayed.
we are hanging our hopes on Denner, but what if he is content with a BO price of $12-13 or about 3x his cost? Or a profit of about $200 million?
thanks
thanks